文献速递胸部肿瘤支持与姑息治疗

胸部恶性肿瘤患者COVID-19:TERAVOLT国际登记队列研究首报

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
PubMed 文献 · Lancet Oncol · 2020-06-12

TERAVOLT是一项国际多中心登记研究,纳入8国200例胸部恶性肿瘤合并COVID-19患者,中位年龄68岁,76%住院,33%死亡。单因素分析显示年龄>65岁、吸烟史、单纯化疗及合并症与死亡风险升高相关,多因素分析仅吸烟史与死亡风险独立相关。

要点

  • 胸部恶性肿瘤合并COVID-19患者死亡率高,住院率76%,死亡率33%。
  • 符合ICU指征者仅10%入住ICU,重症监护资源使用率低。

核心结论

  • 胸部恶性肿瘤合并COVID-19患者死亡率高且ICU入住率低。
  • 吸烟史与死亡风险独立相关,是否可通过ICU治疗降低死亡率尚待确定。

研究设计与样本

  • TERAVOLT为多中心观察性研究,含横断面和纵向队列两部分。
  • 本次分析纳入2020年3月26日至4月12日8国200例胸部恶性肿瘤合并COVID-19患者。

主要发现

  • 152例(76%)住院,66例(33%)死亡。
  • 符合ICU指征的134例中仅13例(10%)入住ICU。

临床怎么用

  • 对胸部恶性肿瘤合并COVID-19患者应评估吸烟史等死亡风险因素。
  • ICU收治决策建议在多学科框架下结合肿瘤特异性死亡风险和患者意愿讨论。

局限性

  • 本文为前200例患者的初步分析, registry仍在继续纳入新中心和患者数据。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies. METHODS: The Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry is a multicentre observational study composed of a cross-sectional component and a longitudinal cohort component. Eligibility criteria were the presence of any thoracic cancer (non-small-cell lung cancer [NSCLC], small-cell lung cancer, mesothelioma, thymic epithelial tumours, and other pulmonary neuroendocrine neoplasms) and a COVID-19 diagnosis, either laboratory confirmed with RT-PCR, suspected with symptoms and contacts, or radiologically suspected cases with lung imaging features consistent with COVID-19 pneumonia and symptoms. Patients of any age, sex, histology, or stage were considered eligible, including those in active treatment and clinical follow-up. Clinical data were extracted from medical records of consecutive patients from Jan 1, 2020, and will be collected until the end of pandemic declared by WHO. Data on demographics, oncological history and comorbidities, COVID-19 diagnosis, and course of illness and clinical outcomes were collected. Associations between demographic or clinical characteristics and outcomes were measured with odds ratios (ORs) with 95% CIs using univariable and multivariable logistic regression, with sex, age, smoking status, hypertension, and chronic obstructive pulmonary disease included in multivariable analysis. This is a preliminary analysis of the first 200 patients. The registry continues to accept new sites and patient data. FINDINGS: Between March 26 and April 12, 2020, 200 patients with COVID-19 and thoracic cancers from eight countries were identified and included in the TERAVOLT registry; median age was 68·0 years (61·8-75·0) and the majority had an Eastern Cooperative Oncology Group performance status of 0-1 (142 [72%] of 196 patients), were current or former smokers (159 [81%] of 196), had non-small-cell lung cancer (151 [76%] of 200), and were on therapy at the time of COVID-19 diagnosis (147 [74%] of 199), with 112 (57%) of 197 on first-line treatment. 152 (76%) patients were hospitalised and 66 (33%) died. 13 (10%) of 134 patients who met criteria for ICU admission were admitted to ICU; the remaining 121 were hospitalised, but were not admitted to ICU. Univariable analyses revealed that being older than 65 years (OR 1·88, 95% 1·00-3·62), being a current or former smoker (4·24, 1·70-12·95), receiving treatment with chemotherapy alone (2·54, 1·09-6·11), and the presence of any comorbidities (2·65, 1·09-7·46) were associated with increased risk of death. However, in multivariable analysis, only smoking history (OR 3·18, 95% CI 1·11-9·06) was associated with increased risk of death. INTERPRETATION: With an ongoing global pandemic of COVID-19, our data suggest high mortality and low admission to intensive care in patients with thoracic cancer. Whether mortality could be reduced with treatment in intensive care remains to be determined. With improved cancer therapeutic options, access to intensive care should be discussed in a multidisciplinary setting based on cancer specific mortality and patients' preference. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Garassino MC, Whisenant JG, Huang LC, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020. PMID: 32539942. doi:10.1016/S1470-2045(20)30314-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。